Underwriting Update from America (ALUCA RiskeBusiness)
This update is based largely upon findings from our 2018 New Business Critical Issues Survey. It was conducted over a span of six months stating in October 2017. Chief underwriters from 93 insurers offering individually underwritten life insurance participated in this survey.
The Casual Liver Enzyme Elevation
Liver enzyme testing (LFTs) are part of virtually every blood profile obtained on a potential insured. They are also one of the leading causes of a completely unexpected rating or decline on a case. Most clients do not provide a specific history for an elevation, and no broker or agent expects such an outcome with what seemed to be a clean history. Knowing how to approach this situation can be key to a favorable underwriting outcome.
Wearable Technology in Life Insurance: Gadget or Gimmick?
Is the promise of wearable technology too good to be true? Inclusion of wearables in life insurance products to date has not matched the interest. But advances hold great promise. RGA’s Julianne Callaway explores the power and perils of these promising devices in Digital Insurance.
Influenza: The Insurers' Perspective (ALUCA RiskeBusiness)
Seasonal influenza is a unique public health conundrum: its epidemics are annual, yet even with the wealth of epidemiologic data now collected on it, predicting its activity and severity still remains a significant challenge. Recent modeling suggests that the global burden of influenza is worse than previously thought, accounting for up to 600,000 deaths annually.
LOMA Resource: Global Update - Pressures and Possibilities
What effect will changing—and challenging—economies, politics, and regulations have on life insurance companies worldwide?
Be Kind to Your Genes: An Insurance Perspective on the Fast-Growing Field of Epigenetics
Eat your vegetables. Stay active. Avoid smoking. Keep out of the sun. Patients have been hearing this good advice from their doctors for a long time. Now, researchers are uncovering new evidence that our lifestyle choices can measurably influence mortality risk at a genetic level. Learn more about the emerging science of epigenetics in a two-part interview and the webinar “Epigenetics and Liquid Biopsies: Fact, Fiction or Both.”
How Wearable Technology Presents Opportunity For Insurers
Wearable devices (those worn by consumers as accessories or implants), have been of interest to more than a handful of industries in recent years. The opportunities and possible uses so far seem positive and limitless.
Frictionless Business and the Future of Life Insurance
The age of traditional business partnerships is long past. Today, strategic partnerships offer life insurers the ability to expand their businesses into new ecosystems. Whether investing in insurtechs or collaborating with partners in complementary industries, life insurers can build partnerships based not only on strategy, product and services but also on the merging of technology and the sharing of platforms.
How Liquid Biopsies Could Transform Insurance Medicine
Cancerous tumors shed whole cells or tiny bits of DNA and other genetic material into the bloodstream and other bodily fluids. This allows clinicians to potentially analyze blood samples to detect a tumor's unique mutations and offer a personalized treatment regimen, all without an invasive tissue biopsy.
Why Data Veracity Will Reshape Life Insurance
From its earliest days, life insurance has been fueled by data. Today, the industry is more data-driven than ever. Life insurers rely on data to make better operational, risk and pricing decisions. They use data to develop new products and business models. Increasingly, they leverage data to incentivize customers to reduce their exposure to risks and help them avoid incurring losses.